MedTrace Logo

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

NCT00446836 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2016-03-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Paclitaxel polyglumex (Xyotax)

biologically enhanced chemotherapeutic

Sponsors & Collaborators

  • Cellular Therapeutics

    collaborator UNKNOWN

  • The Methodist Hospital Research Institute

    lead OTHER

Principal Investigators

  • Robert J Amato, DO · Baylor College of Medicine - Methodist Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-11-30
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00446836 on ClinicalTrials.gov